ROCR Value Based Program Act

The ROCR Value Based Program Act (S.1031), introduced on March 13, 2025, aims to establish a specialized Medicare payment program for radiation oncology services. This program would transition from fee-for-service to episode-of-care payments, providing a more stable revenue model for providers and manufacturers of radiation therapy equipment and software. The bill was read twice and referred to the Senate Committee on Finance on the same day it was introduced. A companion bill, HR2120, has also been introduced in the House, indicating bipartisan and bicameral interest in this policy. This bill does not authorize or appropriate a specific dollar amount but rather changes the payment mechanism for existing Medicare spending on radiation oncology services, which was approximately $4.2 billion in 2021. The shift to episode-of-care payments is intended to incentivize patient-centered, efficient, and high-value care, moving away from systems that historically incentivized higher volumes. The bill also includes an exception for providing free or discounted transportation for radiation oncology patients. Structural beneficiaries of this legislation, if enacted, would include manufacturers of radiation therapy equipment and software, as well as radiation oncology providers. Companies like GE HealthCare Technologies Inc. ($GEHC), which produces medical imaging and oncology solutions, could see increased revenue predictability from this payment model. While Pfizer Inc. ($PFE) is a pharmaceutical company, its involvement in cancer treatments means that a more stable and efficient radiation oncology sector could indirectly support overall cancer care pathways. Looking at recent market data, $GEHC has seen a 7-day change of +2.37% but a 30-day change of -8.7%, with its current price at $70.4. $PFE has experienced a 7-day change of +0.22% and a 30-day change of +4.58%, currently trading at $27.83. These movements are not directly attributable to S.1031 given its early stage. The bill's progression requires committee consideration in both the Senate and House, followed by potential floor votes and reconciliation, a process that typically takes several months to years. Given its early stage, the bill's impact on market sentiment is currently neutral. The presence of a companion bill (HR2120) suggests a coordinated effort, which can increase the likelihood of eventual passage. However, the bill still needs to navigate committee review and votes in both chambers.